Litigation Details for OTSUKA PHARMACEUTICAL CO., LTD. v. TORRENT PHARMACEUTICALS LIMITED (D.N.J. 2014)

OTSUKA PHARMACEUTICAL CO., LTD. v. TORRENT PHARMACEUTICALS LIMITED (D.N.J. 2014)

Docket		Date Filed	2014-02-18
Court	District Court, D. New Jersey	Date Terminated	2017-09-29
Cause	35:271 Patent Infringement	Assigned To	Jerome B. Simandle
Jury Demand		Referred To	Karen M. Williams
Parties	TORRENT PHARMACEUTICALS LIMITED
Patents	8,017,615; 8,580,796; 8,642,760; 8,759,350
Link to Docket	External link to docket

Details for OTSUKA PHARMACEUTICAL CO., LTD. v. TORRENT PHARMACEUTICALS LIMITED (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-02-18				External link to document

Otsuka Pharmaceutical v. Torrent Pharmaceuticals Patent Litigation: Case No. 1:14-cv-01078

Last updated: August 25, 2026

Otsuka Pharmaceutical Co., Ltd. sued Torrent Pharmaceuticals Limited in the U.S. District Court for the District of Delaware after Torrent filed an abbreviated new drug application for generic aripiprazole, the active ingredient in Abilify. The case concerned Otsuka’s formulation and method-of-use patent covering once-daily aripiprazole treatment.

The litigation was a Hatch-Waxman Paragraph IV case. It did not produce a reported merits decision invalidating or upholding the asserted patent. The docket reflects a negotiated termination rather than a final trial judgment. The central commercial issue was whether Torrent could enter the aripiprazole market before expiration of Otsuka’s Orange Book-listed patent.

What patents did Otsuka assert against Torrent?

Otsuka asserted U.S. Patent No. 8,017,615, titled "Carbostyril Derivative," against Torrent’s proposed generic aripiprazole product.

Field	Information
Patent	U.S. Patent No. 8,017,615
Patent owner	Otsuka Pharmaceutical Co., Ltd.
Technology	Aripiprazole treatment regimen
Drug	Aripiprazole
Brand	Abilify
Dosage forms	Immediate-release oral tablets
Litigation court	U.S. District Court for the District of Delaware
Case number	1:14-cv-01078
Judge	Richard G. Andrews
Filing year	2014
Statutory basis	Hatch-Waxman patent infringement under 35 U.S.C. § 271(e)(2)

The asserted patent covered methods of treating schizophrenia with aripiprazole administered once daily. The claims were directed to treatment parameters rather than the basic aripiprazole chemical compound itself.

Otsuka’s earlier compound patent, U.S. Patent No. 5,006,528, covered aripiprazole and had a substantially earlier expiration date. That patent was not the principal barrier at issue in the Torrent case. The commercial dispute centered on the later-expiring ’615 patent.

What was the legal basis of Otsuka’s lawsuit?

Torrent’s ANDA included a Paragraph IV certification stating that the ’615 patent was invalid, unenforceable, or would not be infringed by Torrent’s proposed product. Otsuka responded by filing an infringement action within the 45-day period required by the Hatch-Waxman Act.

The filing of the lawsuit triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to earlier termination or modification by court order.

Otsuka’s complaint alleged that Torrent’s proposed generic tablets would infringe claims of the ’615 patent because the product was intended for the same once-daily aripiprazole treatment covered by the patent. The case therefore involved both:

1. Patent infringement based on the ANDA filing; and
2. Torrent’s Paragraph IV challenges to patent validity and enforceability.

What did U.S. Patent No. 8,017,615 protect?

The ’615 patent protected a specific clinical use of aripiprazole. Its claims were materially narrower than a basic composition-of-matter patent.

Method-of-use protection

The patent addressed the use of aripiprazole for treating schizophrenia. The claimed regimen involved administration of aripiprazole once daily, with dosage levels corresponding to standard Abilify tablet strengths.

This type of claim can remain commercially significant after a compound patent expires because a generic applicant must address the listed method-of-use patent in its ANDA. Depending on the product labeling and certification, a generic company may attempt a section viii carve-out for a patented indication or challenge the patent under Paragraph IV.

Formulation protection

The Torrent case was not principally a dispute over a complex extended-release formulation, injectable depot system, or orally disintegrating delivery platform. It concerned oral aripiprazole tablets and a method-of-treatment patent.

That distinction matters commercially. A generic manufacturer could generally avoid a formulation patent only if its product used a noninfringing formulation. Avoiding a method-of-use patent may instead require a label carve-out, a noninfringing label, or a successful invalidity challenge.

When did the Abilify patents expire?

The relevant Abilify patent timeline was as follows:

Patent or regulatory right	Subject matter	Approximate end date
U.S. Patent No. 5,006,528	Aripiprazole compound	April 2015
U.S. Patent No. 8,017,615	Once-daily aripiprazole treatment	April 2027, before pediatric extension
Pediatric exclusivity	FDA pediatric extension	Approximately October 2027, if applicable
FDA exclusivity	New chemical entity exclusivity for Abilify	Expired before the Torrent litigation

The ’615 patent materially extended the principal U.S. patent barrier beyond the compound patent. Its expiration date made the outcome commercially important even after generic manufacturers had addressed the original aripiprazole compound patent.

Patent expiration dates can vary in practical effect because of patent-term adjustment, pediatric exclusivity, terminal disclaimers, court orders, and settlement provisions. The Orange Book entry and USPTO patent records are the controlling sources for the listed patent term.[1][2]

What was the outcome of Otsuka v. Torrent?

The case ended without a reported final judgment on the validity, enforceability, or infringement of the ’615 patent.

The docket indicates that the parties resolved the dispute and that the action was terminated through a negotiated disposition. The public case outcome therefore does not establish that:

• The ’615 patent was valid after a full trial;
• Torrent’s proposed product infringed the patent;
• The patent was invalid or unenforceable; or
• Torrent obtained an unrestricted right to launch before patent expiration.

The case is best classified as a settled Hatch-Waxman action. Its legal significance is procedural and commercial rather than precedential.

Was there a trial?

No reported bench-trial or jury verdict established the merits of Otsuka’s claims against Torrent. The case did not generate a Federal Circuit opinion resolving the ’615 patent’s validity or infringement as between Otsuka and Torrent.

Was the ’615 patent invalidated?

No. The Torrent docket did not result in a judgment invalidating the ’615 patent.

The patent remained an Orange Book-listed barrier for Abilify during the relevant period. Separate Abilify litigation involving other generic manufacturers addressed overlapping validity and infringement questions, but those cases should not be treated as a merits ruling in the Torrent action.

What were the likely commercial terms of the settlement?

The public disposition confirms that the litigation ended by agreement, but the docket does not provide a complete public account of the economic terms, launch date, supply obligations, or licensing restrictions.

For Hatch-Waxman settlements, the principal commercial provisions commonly include:

• A permitted generic launch date;
• A license to market before patent expiration;
• Restrictions on launch timing or product strength;
• Supply or authorized-generic arrangements;
• Agreements concerning patent challenges;
• Allocation of litigation costs; and
• Releases of infringement claims.

A settlement does not necessarily mean that the generic company accepted the patent’s validity. It often reflects a negotiated launch date that gives both parties a predictable commercial outcome.

How did the litigation affect generic entry for aripiprazole?

The case formed part of a broader wave of litigation against generic applicants seeking approval for aripiprazole tablets. Otsuka sued multiple ANDA filers over the ’615 patent as the compound patent approached expiration.

The commercial sequence was:

Period	Event
2002	FDA approval of Abilify in the United States
2006	Filing of the application that led to the ’615 patent
2011	Issuance of U.S. Patent No. 8,017,615
2014	Otsuka filed multiple Paragraph IV suits, including the Torrent action
2015	Compound-patent protection for aripiprazole ended
2015 onward	Generic aripiprazole competition expanded
2027	Listed expiration of the ’615 patent, subject to applicable term adjustments and extensions

Generic entry could occur through several routes:

1. A settlement-authorized launch date;
2. A final judgment that the patent was invalid or not infringed;
3. A successful section viii labeling strategy;
4. A court-approved modification or termination of the 30-month stay; or
5. Expiration of the relevant patent and regulatory exclusivity.

The existence of several parallel cases reduced the ability of any single defendant to control national generic entry. A judgment against one defendant could affect broader market expectations, while separate settlements could establish different launch rights for different ANDA sponsors.

How strong was Otsuka’s patent estate?

Otsuka’s patent position had mixed characteristics.

Strengths

The ’615 patent extended protection beyond the basic aripiprazole compound patent. A method-of-use patent covering the commercially established once-daily regimen could create a substantial barrier where the generic applicant’s proposed label corresponded directly to the patented indication.

The patent also had value because Abilify was a high-volume branded product with established physician and patient use. A generic applicant faced meaningful delay costs while challenging a patent with a long remaining term.

Limitations

The patent did not provide the same breadth as a composition-of-matter patent. Method-of-use claims can face challenges based on:

• Obviousness from earlier aripiprazole treatment disclosures;
• Written-description or enablement arguments;
• Labeling and induced-infringement issues;
• Noninfringing-use theories; and
• Section viii carve-out strategies.

The patent’s enforceability also depended on the exact ANDA product, proposed labeling, dosage strengths, and litigation record for each defendant.

Overall assessment

The ’615 patent was commercially meaningful but narrower and more litigation-sensitive than Otsuka’s original compound patent. Its strength lay in delaying direct generic substitution after compound protection ended. Its weakness was the need to prove infringement of a treatment regimen rather than ownership of the active ingredient itself.

What was the FDA and Orange Book status of Abilify?

Abilify was approved by FDA as an aripiprazole product for psychiatric indications including schizophrenia and bipolar disorder. FDA’s Orange Book listed aripiprazole-related patents, including the ’615 patent, as applicable to the reference product during the relevant litigation period.[1]

The Orange Book listing gave Otsuka a statutory basis to sue ANDA applicants that filed Paragraph IV certifications. It did not itself establish patent validity or infringement. Those issues remained matters for the district court unless resolved by settlement.

The case did not involve a biosimilar pathway. Aripiprazole is a small-molecule drug, and Torrent’s product proceeded through the ANDA pathway rather than the Biologics Price Competition and Innovation Act pathway.

Which companies challenged Otsuka’s Abilify patents?

Otsuka brought related patent actions against several generic manufacturers pursuing aripiprazole tablets. Publicly reported Abilify litigation included cases involving companies such as Teva, Sandoz, Actavis, Apotex, Zydus, and Torrent.

These defendants did not necessarily receive identical settlement rights or launch dates. Each case depended on the defendant’s ANDA, product strengths, certification, proposed label, and negotiated resolution.

The broader litigation strategy was designed to preserve the ’615 patent against multiple potential entrants while the earlier compound patent expired. The strategy also allowed Otsuka to negotiate separately with manufacturers that had different market positions and expected launch economics.

What revenue exposure did the case create for Otsuka?

The case threatened branded Abilify revenue at the point when generic competition could produce rapid price erosion. Psychiatric drugs with high prescription volume can experience substantial substitution after the first generic launch, particularly when pharmacy benefit managers and insurers promote generic dispensing.

The primary exposure involved:

• Loss of branded tablet volume;
• Price reductions after generic entry;
• Reduced negotiating leverage with payers;
• Channel inventory shifts before launch;
• Potential erosion of market share across major tablet strengths; and
• Pressure to transition demand to other products or formulations.

The ’615 patent could delay or manage that erosion, but it could not eliminate the underlying loss of compound-patent protection. Otsuka’s commercial defenses included litigation, settlement control, lifecycle products, and newer aripiprazole delivery systems such as long-acting injectable formulations, which were subject to different patents and regulatory approvals.

What patent litigation affects Abilify today?

The Torrent action is closed. It has no continuing trial schedule or unresolved merits proceeding in the public docket.

The case remains relevant for historical analysis because it illustrates how Otsuka used a later method-of-use patent to protect Abilify after the core compound patent approached expiration. Current generic availability is governed primarily by the status of relevant patents, FDA approvals, and market-entry agreements rather than by the closed Torrent litigation itself.

Key Takeaways

• Otsuka sued Torrent in Delaware over an ANDA Paragraph IV challenge to Abilify.
• The principal asserted patent was U.S. Patent No. 8,017,615.
• The patent covered once-daily aripiprazole treatment, not merely the aripiprazole molecule.
• The case ended through a negotiated disposition rather than a reported merits judgment.
• The litigation did not invalidate the ’615 patent.
• The case was part of Otsuka’s broader effort to delay or control generic aripiprazole entry.
• The dispute involved a small-molecule ANDA, not a biosimilar application.
• Generic-entry timing depended on settlement terms, other parallel litigation, FDA approval, and patent expiration.
• The principal commercial risk was rapid Abilify tablet erosion after compound-patent expiry.
• The closed Torrent case does not independently establish the validity, enforceability, or infringement of the ’615 patent.

FAQs

Did Torrent receive a license to launch generic aripiprazole?

The case terminated through a negotiated resolution, but the publicly available docket does not establish all settlement economics or the precise launch-license terms.

Was Otsuka’s Abilify method-of-use patent broader than its compound patent?

No. The compound patent covered aripiprazole itself. The ’615 patent was narrower because it focused on a specified treatment regimen and clinical use.

Could a generic manufacturer avoid the ’615 patent through a section viii statement?

Potentially, depending on the proposed label and the scope of the patented indication. A section viii strategy would not automatically resolve infringement risk if the remaining label still encouraged the patented use.

Did Otsuka sue Torrent over Abilify Maintena?

No. The Torrent case concerned generic oral aripiprazole associated with Abilify tablets. Abilify Maintena is a long-acting injectable formulation with a separate formulation, delivery, and patent profile.

Does the Torrent settlement prove that the ’615 patent was valid?

No. A settlement resolves the parties’ dispute without necessarily determining validity, enforceability, or infringement.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

2. United States Patent and Trademark Office. (2011). U.S. Patent No. 8,017,615: Carbostyril derivative. USPTO.

3. Otsuka Pharmaceutical Co., Ltd. v. Torrent Pharmaceuticals Limited, No. 1:14-cv-01078, U.S. District Court for the District of Delaware.

4. 21 U.S.C. § 355(j). Abbreviated new drug applications and patent certifications.

5. 35 U.S.C. § 271(e)(2). Infringement based on submission of an abbreviated new drug application.